Navigation Links
Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
Date:11/10/2008

d, that third parties on whom we depend will perform as anticipated, or that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and therapeutic hypothermia devices and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our ability to successfully accelerate the commercialization of our therapeutic hypothermia devices and launch new devices within the timeframes contemplated, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2008 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com.

Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium
Therapeutics, Inc. Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM)

are trademarks of Tissue Repair Company. InnerCool Therapies(R), InnerCool(R), Celsius Control System(R),

RapidBlue(TM
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
2. ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels
3. Cardium Announces InnerCools New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification
4. Cardium Announces Follow-On Direct Investment by Institutional Investor
5. Cardium Selected for Inclusion in Russell Microcap Index
6. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
7. Cardium Launches New AWARE Clinical Study Website
8. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
9. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
10. Cardium Reports on First Quarter 2008 Highlights and Financial Results
11. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PharmaBoardroom,s new report, , Healthcare and Life ... free download , digs deep into this vibrant market, speaking ... today. One area where Algeria ... homegrown pharmaceutical manufacturing base, even if the government,s ambitious target ... A cursory comparison with neighboring Morocco ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of ... Nick Maroulis, Pharm.D. to the newly created position of ... this position, Dr. Maroulis will continue to manage the ... our multi-site pharmacies as the company expands. Dr. Maroulis ... time he has served in many different capacities in ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... Huifeng Bio-,Pharmaceutical Technology, Inc (OTC Bulletin Board: HFGB), ... pharmaceutical raw materials,for use in pharmaceutical, nutraceutical and ... results second quarter 2008 which,ended June 30 on ... close., Huifeng,s earnings release and related materials ...
... Anacor Pharmaceuticals,announced today that it has appointed Kurt Jarnagin, ... are pleased to welcome Kurt to the company," said ... Pharmaceuticals. "Kurt,is a noted expert in the field of ... enrich our team as we continue to,expand our pipeline ...
... ACEL ) today announced that it received ... notifying the Company that its,securities will be delisted ... NASDAQ notified the Company that the market value ... $35 million required for continued,inclusion on The NASDAQ ...
Cached Biology Technology:Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research 2Alfacell Receives NASDAQ Delisting Letter 2Alfacell Receives NASDAQ Delisting Letter 3
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:11/21/2014)... DALLAS , November 18, 2014 ... Security Systems Market by Systems (Video, RFID, Access Control, ... (SEZ, Factories, Hotels, Banks, Government), Component Service Geography - ... Security Systems Market is projected to be around $25 ... Billion by 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... are very fragile and highly susceptible to ... in ways to increase profits and reduce ... temperature management techniques. Collaborative research from scientists ... the University of Florida contains several findings ...
... wet climate and a lot of different kinds of birds ... the region will also contain numerous kinds of pathogens that ... of human disease, led by Dr. Rob Dunn at North ... social scientists, shows that that one can predict the number ...
... Press Program will feature new study results from the ... of their presentation at ELCC): Making ... with radiation in patients with locally advanced lung cancer: ... for lung cancer in organ transplant recipients, Hyperfractionated radiotherapy ...
Cached Biology News:Hydrocooling shows promise for reducing strawberry weight loss, bruising 2Study pins factors behind geography of human disease 2Study pins factors behind geography of human disease 32nd European Lung Cancer Conference 22nd European Lung Cancer Conference 3
...
... Monoclonal Anti-β-Tubulin IV Recognizes an ... sequence of β-tubulin isotype IV. ... isotypes is observed. ascites fluid ... C-terminal sequence of β-tubulin isotype ...
... Finnpipette BioControl is a major step ... complete liquid handling system - with ... tip cone modules. All five single ... modules fit one handle. The lightweight ...
... the joining of two strands of DNA ... of adjacent nucleotides in either a cohesive-ended ... also been shown to catalyze the joining ... RNA strand in a duplex molecule but ...
Biology Products: